WilmerHale Represents Exo Therapeutics in its $78M Series B Financing

WilmerHale Represents Exo Therapeutics in its $78M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On October 5, 2021, Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, announced the completion of a $78 million Series B financing. Proceeds will be used to advance therapeutic candidates in oncology and inflammation derived from the company’s proprietary ExoSightTM platform towards proof-of-concept and into the clinic. Additionally, proceeds will be used to expand Exo’s pursuit of new targets with the ExoSight platform.

The WilmerHale team representing Exo Therapeutics was led by Jason Kropp and included Erin Garrity, Sara Uz and Alex Bloom.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel